Skip to main content
Top
Published in: Diabetologia 3/2010

Open Access 01-03-2010 | Article

Human IL6 enhances leptin action in mice

Authors: M. Sadagurski, L. Norquay, J. Farhang, K. D’Aquino, K. Copps, M. F. White

Published in: Diabetologia | Issue 3/2010

Login to get access

Abstract

Aims/hypothesis

Interleukin-6 is an inflammatory cytokine with pleiotropic effects upon nutrient homeostasis. Many reports show that circulating IL6 correlates with obesity and contributes to insulin resistance; however, IL6 can promote energy expenditure that improves glucose homeostasis.

Methods

We investigated nutrient homeostasis in C57BL/6J mice with sustained circulating human IL6 (hIL6) secreted predominantly from brain and lung (hIL6 tg mice).

Results

The hIL6 tg mice displayed no features of systemic inflammation and were more insulin-sensitive than wild-type mice. On a high-fat diet, hIL6 tg mice were lean, had low leptin concentrations, consumed less food and expended more energy than wild-type mice. Like ob/ob mice, the ob/ob IL6 mice (generated by intercrossing ob/ob and hIL6 tg mice) were obese and glucose-intolerant. However, low-dose leptin injections increased physical activity and reduced both body weight and food intake in ob/ob IL6 mice, but was ineffective in ob/ob mice. Leptin increased hypothalamic signal transducer and activator of transcription-3 phosphorylation in ob/ob IL6 mice, whereas ob/ob mice barely responded.

Conclusions/interpretation

Human IL6 enhanced central leptin action in mice, promoting nutrient homeostasis and preventing diet-induced obesity.
Appendix
Available only for authorised users
Literature
1.
go back to reference Glund S, Krook A (2008) Role of interleukin-6 signalling in glucose and lipid metabolism. Acta Physiol (Oxf) 192:37–48 Glund S, Krook A (2008) Role of interleukin-6 signalling in glucose and lipid metabolism. Acta Physiol (Oxf) 192:37–48
2.
go back to reference Febbraio MA (2007) gp130 receptor ligands as potential therapeutic targets for obesity. J Clin Invest 117:841–849CrossRefPubMed Febbraio MA (2007) gp130 receptor ligands as potential therapeutic targets for obesity. J Clin Invest 117:841–849CrossRefPubMed
5.
go back to reference Vozarova B, Weyer C, Hanson K, Tataranni PA, Bogardus C, Pratley RE (2001) Circulating interleukin-6 in relation to adiposity, insulin action, and insulin secretion. Obes Res 9:414–417CrossRefPubMed Vozarova B, Weyer C, Hanson K, Tataranni PA, Bogardus C, Pratley RE (2001) Circulating interleukin-6 in relation to adiposity, insulin action, and insulin secretion. Obes Res 9:414–417CrossRefPubMed
6.
go back to reference Carey AL, Bruce CR, Sacchetti M et al (2004) Interleukin-6 and tumor necrosis factor-alpha are not increased in patients with type 2 diabetes: evidence that plasma interleukin-6 is related to fat mass and not insulin responsiveness. Diabetologia 47:1029–1037PubMed Carey AL, Bruce CR, Sacchetti M et al (2004) Interleukin-6 and tumor necrosis factor-alpha are not increased in patients with type 2 diabetes: evidence that plasma interleukin-6 is related to fat mass and not insulin responsiveness. Diabetologia 47:1029–1037PubMed
7.
go back to reference Petersen AM, Pedersen BK (2006) The role of IL-6 in mediating the anti-inflammatory effects of exercise. J Physiol Pharmacol 57(Suppl 10):43–51PubMed Petersen AM, Pedersen BK (2006) The role of IL-6 in mediating the anti-inflammatory effects of exercise. J Physiol Pharmacol 57(Suppl 10):43–51PubMed
8.
go back to reference Pedersen BK, Febbraio MA (2008) Muscle as an endocrine organ: focus on muscle-derived interleukin-6. Physiol Rev 88:1379–1406CrossRefPubMed Pedersen BK, Febbraio MA (2008) Muscle as an endocrine organ: focus on muscle-derived interleukin-6. Physiol Rev 88:1379–1406CrossRefPubMed
9.
go back to reference Senn JJ, Klover PJ, Nowak IA, Mooney RA (2002) Interleukin-6 induces cellular insulin resistance in hepatocytes. Diabetes 51:3391–3399CrossRefPubMed Senn JJ, Klover PJ, Nowak IA, Mooney RA (2002) Interleukin-6 induces cellular insulin resistance in hepatocytes. Diabetes 51:3391–3399CrossRefPubMed
10.
go back to reference Senn JJ, Klover PJ, Nowak IA et al (2003) Suppressor of cytokine signaling-3 (SOCS-3), a potential mediator of interleukin-6-dependent insulin resistance in hepatocytes. J Biol Chem 278:13740–13746CrossRefPubMed Senn JJ, Klover PJ, Nowak IA et al (2003) Suppressor of cytokine signaling-3 (SOCS-3), a potential mediator of interleukin-6-dependent insulin resistance in hepatocytes. J Biol Chem 278:13740–13746CrossRefPubMed
11.
go back to reference Kim HJ, Higashimori T, Park SY et al (2004) Differential effects of interleukin-6 and -10 on skeletal muscle and liver insulin action in vivo. Diabetes 53:1060–1067CrossRefPubMed Kim HJ, Higashimori T, Park SY et al (2004) Differential effects of interleukin-6 and -10 on skeletal muscle and liver insulin action in vivo. Diabetes 53:1060–1067CrossRefPubMed
12.
go back to reference Klover PJ, Zimmers TA, Koniaris LG, Mooney RA (2003) Chronic exposure to interleukin-6 causes hepatic insulin resistance in mice. Diabetes 52:2784–2789CrossRefPubMed Klover PJ, Zimmers TA, Koniaris LG, Mooney RA (2003) Chronic exposure to interleukin-6 causes hepatic insulin resistance in mice. Diabetes 52:2784–2789CrossRefPubMed
13.
go back to reference Klover PJ, Clementi AH, Mooney RA (2005) Interleukin-6 depletion selectively improves hepatic insulin action in obesity. Endocrinology 146:3417–3427CrossRefPubMed Klover PJ, Clementi AH, Mooney RA (2005) Interleukin-6 depletion selectively improves hepatic insulin action in obesity. Endocrinology 146:3417–3427CrossRefPubMed
14.
go back to reference Franckhauser S, Elias I, Rotter SV et al (2008) Overexpression of Il6 leads to hyperinsulinaemia, liver inflammation and reduced body weight in mice. Diabetologia 51:1306–1316CrossRefPubMed Franckhauser S, Elias I, Rotter SV et al (2008) Overexpression of Il6 leads to hyperinsulinaemia, liver inflammation and reduced body weight in mice. Diabetologia 51:1306–1316CrossRefPubMed
15.
go back to reference van Hall G, Steensberg A, Sacchetti M et al (2003) Interleukin-6 stimulates lipolysis and fat oxidation in humans. J Clin Endocrinol Metab 88:3005–3010CrossRefPubMed van Hall G, Steensberg A, Sacchetti M et al (2003) Interleukin-6 stimulates lipolysis and fat oxidation in humans. J Clin Endocrinol Metab 88:3005–3010CrossRefPubMed
16.
go back to reference Petersen EW, Carey AL, Sacchetti M et al (2005) Acute IL-6 treatment increases fatty acid turnover in elderly humans in vivo and in tissue culture in vitro. Am J Physiol Endocrinol Metab 288:E155–E162CrossRefPubMed Petersen EW, Carey AL, Sacchetti M et al (2005) Acute IL-6 treatment increases fatty acid turnover in elderly humans in vivo and in tissue culture in vitro. Am J Physiol Endocrinol Metab 288:E155–E162CrossRefPubMed
17.
go back to reference Carey AL, Steinberg GR, Macaulay SL et al (2006) Interleukin-6 increases insulin-stimulated glucose disposal in humans and glucose uptake and fatty acid oxidation in vitro via AMP-activated protein kinase. Diabetes 55:2688–2697CrossRefPubMed Carey AL, Steinberg GR, Macaulay SL et al (2006) Interleukin-6 increases insulin-stimulated glucose disposal in humans and glucose uptake and fatty acid oxidation in vitro via AMP-activated protein kinase. Diabetes 55:2688–2697CrossRefPubMed
18.
go back to reference Trujillo ME, Sullivan S, Harten I, Schneider SH, Greenberg AS, Fried SK (2004) Interleukin-6 regulates human adipose tissue lipid metabolism and leptin production in vitro. J Clin Endocrinol Metab 89:5577–5582CrossRefPubMed Trujillo ME, Sullivan S, Harten I, Schneider SH, Greenberg AS, Fried SK (2004) Interleukin-6 regulates human adipose tissue lipid metabolism and leptin production in vitro. J Clin Endocrinol Metab 89:5577–5582CrossRefPubMed
19.
go back to reference Pedersen BK, Bruunsgaard H, Ostrowski K et al (2000) Cytokines in aging and exercise. Int J Sports Med 21(Suppl 1):S4–S9CrossRefPubMed Pedersen BK, Bruunsgaard H, Ostrowski K et al (2000) Cytokines in aging and exercise. Int J Sports Med 21(Suppl 1):S4–S9CrossRefPubMed
20.
go back to reference Pedersen BK, Fischer CP (2007) Physiological roles of muscle-derived interleukin-6 in response to exercise. Curr Opin Clin Nutr Metab Care 10:265–271CrossRefPubMed Pedersen BK, Fischer CP (2007) Physiological roles of muscle-derived interleukin-6 in response to exercise. Curr Opin Clin Nutr Metab Care 10:265–271CrossRefPubMed
21.
go back to reference Starkie R, Ostrowski SR, Jauffred S, Febbraio M, Pedersen BK (2003) Exercise and IL-6 infusion inhibit endotoxin-induced TNF-alpha production in humans. FASEB J 17:884–886PubMed Starkie R, Ostrowski SR, Jauffred S, Febbraio M, Pedersen BK (2003) Exercise and IL-6 infusion inhibit endotoxin-induced TNF-alpha production in humans. FASEB J 17:884–886PubMed
22.
go back to reference Wallenius K, Wallenius V, Sunter D, Dickson SL, Jansson JO (2002) Intracerebroventricular interleukin-6 treatment decreases body fat in rats. Biochem Biophys Res Commun 293:560–565CrossRefPubMed Wallenius K, Wallenius V, Sunter D, Dickson SL, Jansson JO (2002) Intracerebroventricular interleukin-6 treatment decreases body fat in rats. Biochem Biophys Res Commun 293:560–565CrossRefPubMed
23.
go back to reference Myers MG, Cowley MA, Munzberg H (2007) Mechanisms of leptin action and leptin resistance. Annu Rev Physiol 70:537–556CrossRef Myers MG, Cowley MA, Munzberg H (2007) Mechanisms of leptin action and leptin resistance. Annu Rev Physiol 70:537–556CrossRef
24.
go back to reference Takahashi N, Patel HR, Qi Y, Dushay J, Ahima RS (2002) Divergent effects of leptin in mice susceptible or resistant to obesity. Horm Metab Res 34:691–697CrossRefPubMed Takahashi N, Patel HR, Qi Y, Dushay J, Ahima RS (2002) Divergent effects of leptin in mice susceptible or resistant to obesity. Horm Metab Res 34:691–697CrossRefPubMed
25.
26.
go back to reference Wallenius V, Wallenius K, Ahren B et al (2002) Interleukin-6-deficient mice develop mature-onset obesity. Nat Med 8:75–79CrossRefPubMed Wallenius V, Wallenius K, Ahren B et al (2002) Interleukin-6-deficient mice develop mature-onset obesity. Nat Med 8:75–79CrossRefPubMed
27.
go back to reference Lieskovska J, Guo D, Derman E (2002) IL-6-overexpression brings about growth impairment potentially through a GH receptor defect. Growth Horm IGF Res 12:388–398CrossRefPubMed Lieskovska J, Guo D, Derman E (2002) IL-6-overexpression brings about growth impairment potentially through a GH receptor defect. Growth Horm IGF Res 12:388–398CrossRefPubMed
28.
go back to reference Withers DJ, Burks DJ, Towery HH, Altamuro SL, Flint CL, White MF (1999) Irs-2 coordinates Igf-1 receptor-mediated beta-cell development and peripheral insulin signalling. Nat Genet 23:32–40PubMed Withers DJ, Burks DJ, Towery HH, Altamuro SL, Flint CL, White MF (1999) Irs-2 coordinates Igf-1 receptor-mediated beta-cell development and peripheral insulin signalling. Nat Genet 23:32–40PubMed
29.
go back to reference Dong X, Park S, Lin X, Copps K, Yi X, White MF (2006) Irs1 and Irs2 signaling is essential for hepatic glucose homeostasis and systemic growth. J Clin Invest 116:101–114CrossRefPubMed Dong X, Park S, Lin X, Copps K, Yi X, White MF (2006) Irs1 and Irs2 signaling is essential for hepatic glucose homeostasis and systemic growth. J Clin Invest 116:101–114CrossRefPubMed
30.
go back to reference Han CY, Chiba T, Campbell JS et al (2006) Reciprocal and coordinate regulation of serum amyloid A vs apolipoprotein A-I and paraoxonase-1 by inflammation in murine hepatocytes. Arterioscler Thromb Vasc Biol 26:1806–1813CrossRefPubMed Han CY, Chiba T, Campbell JS et al (2006) Reciprocal and coordinate regulation of serum amyloid A vs apolipoprotein A-I and paraoxonase-1 by inflammation in murine hepatocytes. Arterioscler Thromb Vasc Biol 26:1806–1813CrossRefPubMed
31.
go back to reference Migita K, Miyashita T, Maeda Y et al (2005) An active metabolite of leflunomide, A77 1726, inhibits the production of serum amyloid A protein in human hepatocytes. Rheumatology (Oxford) 44:443–448CrossRef Migita K, Miyashita T, Maeda Y et al (2005) An active metabolite of leflunomide, A77 1726, inhibits the production of serum amyloid A protein in human hepatocytes. Rheumatology (Oxford) 44:443–448CrossRef
32.
go back to reference Inoue H, Ogawa W, Asakawa A et al (2006) Role of hepatic STAT3 in brain-insulin action on hepatic glucose production. Cell Metab 3:267–275CrossRefPubMed Inoue H, Ogawa W, Asakawa A et al (2006) Role of hepatic STAT3 in brain-insulin action on hepatic glucose production. Cell Metab 3:267–275CrossRefPubMed
33.
go back to reference Lebrun P, Van Obberghen E (2008) SOCS proteins causing trouble in insulin action. Acta Physiol (Oxf) 192:29–36 Lebrun P, Van Obberghen E (2008) SOCS proteins causing trouble in insulin action. Acta Physiol (Oxf) 192:29–36
34.
go back to reference Myers MG Jr (2004) Leptin receptor signaling and the regulation of mammalian physiology. Recent Prog Horm Res 59:287–304CrossRefPubMed Myers MG Jr (2004) Leptin receptor signaling and the regulation of mammalian physiology. Recent Prog Horm Res 59:287–304CrossRefPubMed
35.
go back to reference Buettner C, Pocai A, Muse ED, Etgen AM, Myers MG Jr, Rossetti L (2006) Critical role of STAT3 in leptin's metabolic actions. Cell Metab 4:49–60CrossRefPubMed Buettner C, Pocai A, Muse ED, Etgen AM, Myers MG Jr, Rossetti L (2006) Critical role of STAT3 in leptin's metabolic actions. Cell Metab 4:49–60CrossRefPubMed
36.
go back to reference Seufert J, Kieffer TJ, Habener JF (1999) Leptin inhibits insulin gene transcription and reverses hyperinsulinemia in leptin-deficient ob/ob mice. Proc Natl Acad Sci U S A 96:674–679CrossRefPubMed Seufert J, Kieffer TJ, Habener JF (1999) Leptin inhibits insulin gene transcription and reverses hyperinsulinemia in leptin-deficient ob/ob mice. Proc Natl Acad Sci U S A 96:674–679CrossRefPubMed
37.
go back to reference Ernst M, Jenkins BJ (2004) Acquiring signalling specificity from the cytokine receptor gp130. Trends Genet 20:23–32CrossRefPubMed Ernst M, Jenkins BJ (2004) Acquiring signalling specificity from the cytokine receptor gp130. Trends Genet 20:23–32CrossRefPubMed
38.
go back to reference Schuster B, Kovaleva M, Sun Y et al (2003) Signaling of human ciliary neurotrophic factor (CNTF) revisited. The interleukin-6 receptor can serve as an alpha-receptor for CTNF. J Biol Chem 278:9528–9535CrossRefPubMed Schuster B, Kovaleva M, Sun Y et al (2003) Signaling of human ciliary neurotrophic factor (CNTF) revisited. The interleukin-6 receptor can serve as an alpha-receptor for CTNF. J Biol Chem 278:9528–9535CrossRefPubMed
39.
go back to reference Steinberg GR, Watt MJ, Fam BC et al (2006) Ciliary neurotrophic factor suppresses hypothalamic AMP-kinase signaling in leptin-resistant obese mice. Endocrinology 147:3906–3914CrossRefPubMed Steinberg GR, Watt MJ, Fam BC et al (2006) Ciliary neurotrophic factor suppresses hypothalamic AMP-kinase signaling in leptin-resistant obese mice. Endocrinology 147:3906–3914CrossRefPubMed
40.
go back to reference Febbraio MA, Hiscock N, Sacchetti M, Fischer CP, Pedersen BK (2004) Interleukin-6 is a novel factor mediating glucose homeostasis during skeletal muscle contraction. Diabetes 53:1643–1648CrossRefPubMed Febbraio MA, Hiscock N, Sacchetti M, Fischer CP, Pedersen BK (2004) Interleukin-6 is a novel factor mediating glucose homeostasis during skeletal muscle contraction. Diabetes 53:1643–1648CrossRefPubMed
41.
go back to reference Steensberg A, van Hall G, Osada T, Sacchetti M, Saltin B, Klarlund PB (2000) Production of interleukin-6 in contracting human skeletal muscles can account for the exercise-induced increase in plasma interleukin-6. J Physiol 529(Pt 1):237–242CrossRefPubMed Steensberg A, van Hall G, Osada T, Sacchetti M, Saltin B, Klarlund PB (2000) Production of interleukin-6 in contracting human skeletal muscles can account for the exercise-induced increase in plasma interleukin-6. J Physiol 529(Pt 1):237–242CrossRefPubMed
42.
go back to reference Ruderman NB, Keller C, Richard AM et al (2006) Interleukin-6 regulation of AMP-activated protein kinase. Potential role in the systemic response to exercise and prevention of the metabolic syndrome. Diabetes 55(Suppl 2):S48–S54CrossRefPubMed Ruderman NB, Keller C, Richard AM et al (2006) Interleukin-6 regulation of AMP-activated protein kinase. Potential role in the systemic response to exercise and prevention of the metabolic syndrome. Diabetes 55(Suppl 2):S48–S54CrossRefPubMed
43.
go back to reference Flores MB, Fernandes MF, Ropelle ER et al (2006) Exercise improves insulin and leptin sensitivity in hypothalamus of Wistar rats. Diabetes 55:2554–2561CrossRefPubMed Flores MB, Fernandes MF, Ropelle ER et al (2006) Exercise improves insulin and leptin sensitivity in hypothalamus of Wistar rats. Diabetes 55:2554–2561CrossRefPubMed
44.
45.
go back to reference Raber J, O'Shea RD, Bloom FE, Campbell IL (1997) Modulation of hypothalamic–pituitary–adrenal function by transgenic expression of interleukin-6 in the CNS of mice. J Neurosci 17:9473–9480PubMed Raber J, O'Shea RD, Bloom FE, Campbell IL (1997) Modulation of hypothalamic–pituitary–adrenal function by transgenic expression of interleukin-6 in the CNS of mice. J Neurosci 17:9473–9480PubMed
46.
go back to reference Suematsu S, Matsuda T, Aozasa K et al (1989) IgG1 plasmacytosis in interleukin 6 transgenic mice. Proc Natl Acad Sci U S A 86:7547–7551CrossRefPubMed Suematsu S, Matsuda T, Aozasa K et al (1989) IgG1 plasmacytosis in interleukin 6 transgenic mice. Proc Natl Acad Sci U S A 86:7547–7551CrossRefPubMed
47.
go back to reference Hirano T, Suematsu S, Matsusaka T, Matsuda T, Kishimoto T (1992) The role of interleukin 6 in plasmacytomagenesis. Ciba Found Symp 167:188–196PubMed Hirano T, Suematsu S, Matsusaka T, Matsuda T, Kishimoto T (1992) The role of interleukin 6 in plasmacytomagenesis. Ciba Found Symp 167:188–196PubMed
48.
go back to reference Katsume A, Miyai T, Suzuki H et al (1997) Interleukin-6 overexpression cannot generate serious disorders in severe combined immunodeficiency mice. Clin Immunol Immunopathol 82:117–124CrossRefPubMed Katsume A, Miyai T, Suzuki H et al (1997) Interleukin-6 overexpression cannot generate serious disorders in severe combined immunodeficiency mice. Clin Immunol Immunopathol 82:117–124CrossRefPubMed
49.
go back to reference Fattori E, Della RC, Costa P et al (1994) Development of progressive kidney damage and myeloma kidney in interleukin-6 transgenic mice. Blood 83:2570–2579PubMed Fattori E, Della RC, Costa P et al (1994) Development of progressive kidney damage and myeloma kidney in interleukin-6 transgenic mice. Blood 83:2570–2579PubMed
Metadata
Title
Human IL6 enhances leptin action in mice
Authors
M. Sadagurski
L. Norquay
J. Farhang
K. D’Aquino
K. Copps
M. F. White
Publication date
01-03-2010
Publisher
Springer-Verlag
Published in
Diabetologia / Issue 3/2010
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-009-1580-8

Other articles of this Issue 3/2010

Diabetologia 3/2010 Go to the issue